Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin.
作者信息
Oo Charles, Barrett Joanne, Dorr Albert, Liu Baolian, Ward Penelope
机构信息
F. Hoffman-La Roche, Nutley, New Jersey 07110, USA.
出版信息
Antimicrob Agents Chemother. 2002 Jun;46(6):1993-5. doi: 10.1128/AAC.46.6.1993-1995.2002.
Abstract
Twelve volunteers completed a two-sequence, three-way crossover study of a single 900-mg aspirin dose and multiple doses of 75 mg of oseltamivir in the absence and presence of 900 mg of aspirin. The plasma and urine results demonstrated no pharmacokinetic interaction between oseltamivir and aspirin.
摘要
相似文献
1
Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin.
Antimicrob Agents Chemother. 2002 Jun;46(6):1993-5. doi: 10.1128/AAC.46.6.1993-1995.2002.
2
Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids.
Br J Clin Pharmacol. 2002 Oct;54(4):372-7. doi: 10.1046/j.1365-2125.2002.01678.x.
3
The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.
Drug Metab Dispos. 2002 Jan;30(1):13-9. doi: 10.1124/dmd.30.1.13.
4
Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules.
Int J Pharm. 2003 May 12;257(1-2):297-9. doi: 10.1016/s0378-5173(03)00164-9.
5
Oseltamivir.
Drugs. 1999 Nov;58(5):851-60; discussion 861-2. doi: 10.2165/00003495-199958050-00007.
6
Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.
Eur J Clin Pharmacol. 2003 Sep;59(5-6):411-5. doi: 10.1007/s00228-003-0639-6. Epub 2003 Aug 9.
7
Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.
Clin Pharmacokinet. 1999 Dec;37(6):471-84. doi: 10.2165/00003088-199937060-00003.
8
P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier.
Drug Metab Dispos. 2008 Feb;36(2):427-34. doi: 10.1124/dmd.107.018556. Epub 2007 Nov 26.
9
Effects of alcohol on human carboxylesterase drug metabolism.
Clin Pharmacokinet. 2015 Jun;54(6):627-38. doi: 10.1007/s40262-014-0226-2.
10
[Influenza: a new treatment, oseltamivir].
J Pharm Belg. 2002 Sep-Oct;57(5):97-102.
引用本文的文献
1
Respiratory Viruses: Influenza, RSV, and Adenovirus in Kidney Transplantation.
Semin Nephrol. 2016 Sep;36(5):417-427. doi: 10.1016/j.semnephrol.2016.05.018.
2
Combination activity of neuraminidase inhibitor oseltamivir and α-tocopherol in influenza virus A (H3N2) infection in mice.
Antivir Chem Chemother. 2015 Aug;24(3-4):83-91. doi: 10.1177/2040206616656263. Epub 2016 Jun 24.
3
The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometrics.
Br J Clin Pharmacol. 2012 Dec;74(6):932-9. doi: 10.1111/j.1365-2125.2012.04280.x.
4
Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience.
Adv Ther. 2011 Nov;28(11):927-59. doi: 10.1007/s12325-011-0072-7. Epub 2011 Nov 1.
5
Pharmacokinetics and diffusion into sputum of oseltamivir and oseltamivir carboxylate in adults with cystic fibrosis.
Antimicrob Agents Chemother. 2011 Sep;55(9):4183-7. doi: 10.1128/AAC.00371-11. Epub 2011 Jun 13.
6
Effect of oseltamivir treatment on anticoagulation: a cross-over study in warfarinized patients.
Br J Clin Pharmacol. 2010 Dec;70(6):834-43. doi: 10.1111/j.1365-2125.2010.03780.x.
7
Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.
Clin Pharmacokinet. 2010 Nov;49(11):741-65. doi: 10.2165/11534730-000000000-00000.
8
Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations.
J Antimicrob Chemother. 2010 Apr;65 Suppl 2(Suppl 2):ii5-ii10. doi: 10.1093/jac/dkq015.
9
Safety and pharmacology of oseltamivir in clinical use.
Drug Saf. 2003;26(11):787-801. doi: 10.2165/00002018-200326110-00004.
本文引用的文献
1
The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.
Drug Metab Dispos. 2002 Jan;30(1):13-9. doi: 10.1124/dmd.30.1.13.
2
Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children.
Paediatr Drugs. 2001;3(3):229-36. doi: 10.2165/00128072-200103030-00005.
3
Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine.
J Chromatogr B Biomed Sci Appl. 2000 Aug 18;745(2):373-88. doi: 10.1016/s0378-4347(00)00300-5.
4
Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.
Clin Pharmacokinet. 1999 Dec;37(6):471-84. doi: 10.2165/00003088-199937060-00003.
5
Pharmacokinetics of acetylsalicylic acid and its metabolites at low doses: a compartmental modeling.
Methods Find Exp Clin Pharmacol. 1995 Jan-Feb;17(1):67-77.
6
Clinical pharmacokinetics of the salicylates.
Clin Pharmacokinet. 1985 Mar-Apr;10(2):164-77. doi: 10.2165/00003088-198510020-00004.
7
Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid.
Clin Pharmacokinet. 1989 Nov;17(5):327-44. doi: 10.2165/00003088-198917050-00003.
Zotero 插件